Market Overview

Audentes Therapeutics Initiated Overweight At Wedbush

Share:
Audentes Therapeutics Initiated Overweight At Wedbush

Wedbush has started coverage of Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating and $20 price target, citing the stock as "a compelling opportunity."

Audentes' AAV-based gene therapy programs are targeted at Pompe disease, X-linked multiple myopath and Crigler-Najjar, a rare congenital disease characterized by severely high levels of bilirubin and risk of neurological damage and death. The clinical readouts are expected in 2017 backed by robust pre-clinical data.

Audentes expects to submit INDs for AT982 for the treatment of Pompe disease and AT342 for the treatment of Crigler-Najjar Syndrome Type 1 (CN Type 1) to enter the clinic in the third quarter and fourth quarter of 2016, respectively.

Related Link: Cowen & Company Initiates Coverage On Audentes Therapeutics At Outperform

The company is also developing AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) and AT307 for the treatment of CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The IND submission for these programs is expected in the first quarter 2017 and full-year 2017, respectively.

"We believe BOLD's ability to ensure a reliable commercial supply of its products will minimize the risk of program delays and protect proprietary IP," analyst David Nierengarten wrote in a note.

Data for the first three programs to enter the clinic, AT982, AT342 and AT132 is expected by year-end 2017, which should be predictive of long-term benefit.

Shares of Audentes closed Friday's regular trading at $14.70. The $20 price target represents a potential upside of 36 percent over Friday's close.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BOLD

DateFirmActionFromTo
Sep 2019MaintainsBuy
Apr 2019DowngradesNeutralSell
Apr 2019MaintainsOutperform

View More Analyst Ratings for BOLD
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (BOLD)

View Comments and Join the Discussion!

Imperial Capital Pumps Up Planet Fitness' Price Target

U.S. Dollar Index Lower, Fed Empire Survey Falls